RNA Technologies in Cardiovascular Medicine and Research

Inbunden, Engelska, 2008

Av Volker A. Erdmann, Wolfgang Poller, Jan Barciszewski

3 169 kr

Beställningsvara. Skickas inom 10-15 vardagar

Fri frakt för medlemmar vid köp för minst 249 kr.

In this book the authors review the field and explore the potential role of RNAi and other RNA technologies in cardiovascular medicine and research. They highlight the impressive recent progress but also the hurdles that still must be overcome before this promising technology is finally ready for translation and clinical use.

Produktinformation

Utgivningsdatum2008-07-09
Mått155 x 235 x 25 mm
Vikt729 g
FormatInbunden
SpråkEngelska
Antal sidor358
Upplaga2008
FörlagSpringer-Verlag Berlin and Heidelberg GmbH & Co. KG
ISBN9783540787082

Tillhör följande kategorier

Hjärt- och kärlsjukdomar inom Medicin
Medicinsk utrustning och medicinska tekniker inom Medicin
Medicinsk genetik inom Medicin
Biokemi inom Naturvetenskap och teknik

MicroRNA.- An Overview of MicroRNA.- MicroRNAs and Their Potential.- miRNAs and Their Emerging Role in Cardiac Hypertrophy.- MicroRNAs and the Control of Heart Pathophysiology.- MicroRNA Systems Biology.- RNA Interference.- Targeting Viral Heart Disease by RNA Interference.- Design of siRNAs and shRNAs for RNA Interference: Possible Clinical Applications.- RNA Interference and MicroRNA Modulation for the Treatment of Cardiac Disorders.- Cardiac Delivery of Nucleic Acids by Transcriptional and Transductional Targeting of Adeno-Associated Viral Vectors.- Ribozymes.- Characterization of Hammerhead Ribozymes Potentially Suitable for the Treatment of Hyper-Proliferative Vascular Diseases.- Applications of Ribozymes and Pyrrole–Imidazole Polyamides for Cardiovascular and Renal Diseases.- Noncoding, Aptamer and Antisense RNAs.- Noncoding RNAs in Human Diseases.- Aptamers and siRNAs in Cardiovascular Disease.- Nucleic Acid Aptamers for Cardiovascular Therapeutics.- NF?B Decoy Oligodeoxynucleotide-Based Therapy in Cardiovascular Diseases.- Antisense Therapy for Restenosis Following Percutaneous Coronary Interventions.- Toxic RNA in Pathogenesis of Human Neuromuscular Disorders.